Thanks to its selection for a 产业通商资源部 project, RudaCure Inc. was able to receive support for raw material 制药 production and formulation research for RCI001. In addition, by being selected for the SME Innovation Growth project, the company became able to conduct 国内外 临床试验.
RCI001, which has been attracting attention as a 候选物质 for 干眼症治疗药, demonstrates 抗炎 effects by selectively modulating multifunctional signaling molecules. It is also being developed as an 滴眼液 due to its observed improvement in 泪液分泎 function. This new 候选药物 is targeting 临床试验 entry domestically and internationally next year.
